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Rod Benson2, Thomas Dietrich1 and Paul R. Cooper1*
1 School of Dentistry, Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom, 2 Imagen 
Therapeutics Ltd., Manchester, United Kingdom
Neutrophil extracellular traps (NETs) are DNA-based antimicrobial web-like structures 
whose release is predominantly mediated by reactive oxygen species (ROS); their 
purpose is to combat infections. However, unbalanced NET production and clearance 
is involved in tissue injury, circulation of auto-antibodies and development of several 
chronic diseases. Currently, there is lack of agreement regarding the high-throughput 
methods available for NET investigation. This study, therefore, aimed to develop and 
optimize a high-content analysis (HCA) approach, which can be applied for the assay of 
NET production and for the screening of compounds involved in the modulation of NET 
release. A suitable paraformaldehyde fixation protocol was established to enable HCA of 
neutrophils and NETs. Bespoke and in-built bioinformatics algorithms were validated by 
comparison with standard low-throughput approaches for application in HCA of NETs. 
Subsequently, the optimized protocol was applied to high-content screening (HCS) of 
a pharmaceutically derived compound library to identify modulators of NETosis. Of 56 
compounds assessed, 8 were identified from HCS for further characterization of their 
effects on NET formation as being either inducers, inhibitors or biphasic modulators. 
The effects of these compounds on naïve neutrophils were evaluated by using specific 
assays for the induction of ROS and NET production, while their modulatory activity was 
validated in phorbol 12-myristate 13-acetate-stimulated neutrophils. Results indicated 
the involvement of glutathione reductase, Src family kinases, molecular-target-of- 
Rapamycin, and mitogen-activated-protein-kinase pathways in NET release. The com-
pounds and pathways identified may provide targets for novel therapeutic approaches 
for treating NET-associated pathologies.
Keywords: neutrophil extracellular traps, high-content analysis, high-content screening, nuclear decondensation, 
MaPK, src, mTOr, glutathione reductase
inTrODUcTiOn
Neutrophils are key components of the innate immune response and migrate to infected peripheral 
tissues to combat invading microorganisms (1). Well-known antimicrobial strategies employed by 
neutrophils include phagocytosis, degranulation of antimicrobial peptides and reactive oxygen spe-
cies (ROS) (2). However, another strategy neutrophils utilize for clearing or limiting infections in 
tissues is via their release of neutrophil extracellular traps (NETs) (3).
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The formation and physiological function of NETs were initially 
described as a neutrophil antimicrobial strategy targeted against 
both Gram-positive and Gram-negative bacteria (3). NETs com-
prise extracellular deoxyribonucleic acid (DNA)-fibers that form 
web-like structures that immobilize pathogens, arresting their 
spread within tissues and, eventually, facilitating their death. 
Fundamental steps in NET formation include the production of 
ROS, the de-condensation of nuclear chromatin modulated by 
the peptidylarginine deiminase 4 enzyme, the mixing of DNA 
with granule proteins and, finally, the active extrusion of the 
NETs through the outer cell membrane (4, 5).
Neutrophil extracellular trap structures comprise a DNA back-
bone decorated with neutrophil granule proteins most of which 
have been reported to have antimicrobial properties, including 
histones, neutrophil elastase, and myeloperoxidase (MPO) (3, 6). 
Notably, ineffective NET formation in vivo can result in pathogen 
survival and infection spread, as reported in chronic granuloma-
tous disease (CGD) patients (4). Beside the beneficial antimicro-
bial function of NETs; however, the presence of DNA/protein 
complexes in extracellular tissue has been associated with several 
pathologies. Excessive production and/or delayed or defective 
removal of NETs are understood to play a role in the pathogenesis 
of inflammatory diseases, such as cystic fibrosis (CF) and systemic 
lupus erythematosus (SLE) (7–9). Furthermore, NET structures 
have been implicated in thrombus formation in deep vein throm-
bosis (DVT) (10), in cancer development (11) and rheumatoid 
arthritis (RA) (12, 13). In recent years, an increasing number of 
inflammatory conditions have been proposed to be associated 
with NET production including periodontitis, which is a chronic 
inflammatory disease triggered by an imbalanced bacterial colo-
nization and host response (14). Due to their contradictory func-
tions in human biology and disease, NETs have been described as 
being a “double-edged sword” and their homeostatic control may 
determine the difference between health and disease (15).
Neutrophil extracellular trap assays are frequently based on 
the identification of their components, including DNA or NET-
related proteins, with levels determined by immunostaining, 
immunoblotting, or ELISA (5, 16–18). These methods can be 
low-throughput, and, consequently, are time consuming and/or 
expensive. Furthermore, the application of different techniques 
may contribute to the lack of consistency in findings in the field 
and fuel the controversies raised by several authors regarding 
the validity of some of the previously reported results (19, 20). 
Subsequently, in recent years several alternative approaches have 
been developed to enable relatively high-throughput analysis of 
NETs. Brinkmann et al. (21) published a semi-automated method 
for image-based quantification of NETs using nucleus area and 
chromatin staining intensity. Moussavi-Harami et  al. (22) also 
developed a microfluidic device for the quantification of ROS 
and NETs which utilized whole blood samples and Gavillet et al. 
(23) reported a flow-cytometry based quantification approach. 
Interestingly, Zhao et al. (24) proposed a new technique for the 
identification of suicidal and vital NET release based on the 
integrated use of flow-cytometry and image analysis.
In this paper, we report the development of an innovative 
solution for analyzing NETs using high-content analysis (HCA), 
which combines automated high-throughput imaging with auto-
mated computational data analysis (25). The technology has 
been extensively employed in industry for compound lead iden-
tification and drug discovery processes. Although the technology 
has plenty of application in cell biology (26, 27), this study aims 
for the first time to validate HCA for automatic characterization 
of NETosis. The main advantages of HCA include its ability to 
quantify protein staining intensity, determination of molecular 
subcellular localization, independent cell information, and the 
rapid acquisition of multiparametric data, such as information on 
spatial and temporal variables (28). The investigation of biological 
features is performed using high-resolution image capture by an 
automated fluorescence microscope capable of reading 96-, 384-, 
1536-well plate formats, which dramatically increases the number 
of conditions that can be analyzed simultaneously (29). A notable 
advantage of HCA compared with previously reported high-
throughput technologies for NETs is the capture of data from 
the entire well. Using a completely automated image-capture 
and image-interpretation system, the data obtained by HCA 
represents the average biological response calculated from the 
entire population of cells interacting with the stimulus. This 
feature will notably eliminate user bias from the interpretation 
of neutrophil responses and can potentially address several of 
the controversies raised regarding NET studies (20, 21).
Studies are now focusing on the identification of compounds 
able to pharmacologically modulate NET production for use in 
the treatment of NET-related diseases (30–33). Cell-based HCA 
has been extensively employed for the screening of compound 
libraries, often referred to as high-content screening (HCS), 
which aims to identify novel therapeutic leads (34). Here, we 
report a completely automated method for the analysis and quan-
tification of NETs based on monitoring nuclear de-condensation 
and extracellular DNA release using HCA and apply this for HCS 
of a pharmaceutically derived compound library.
MaTerials anD MeThODs
neutrophil Preparation
Venous blood was collected from healthy volunteers (Ethical 
approval number: 10/H1208/48) and peripheral blood neutrophils 
were isolated using Percoll density gradients and subsequent red 
blood lysis as previously described (35). Neutrophil stimulation 
was induced by exposing cells to 50 nM Phorbol 12-myristate, 
13-acetate (PMA; Sigma P8139) for up to 4 h and inhibited by 
treating cells for 30 min, prior to PMA stimulation, with 10 µM 
Celastrol (Cayman 70950), which is a well-characterized NET 
inhibitor (33).
Paraformaldehyde Fixation of neTs
A 20% paraformaldehyde solution (Sigma P6148) was added 
directly to the neutrophil culture medium providing a final con-
centration of 4% paraformaldehyde. Subsequently, samples were 
incubated for 10 min at room temperature. Plates were then cen-
trifuged for 10 min at 1,800 rcf, medium was carefully removed 
and the resulting fixed samples were washed twice with PBS.
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compound library Preparation
The 56 compounds were diluted in DMSO as per manufacturers’ 
instructions (detailed in Table S1 in Supplementary Material). 
Master plates with compounds at 1,000 times concentration 
were prepared in advance, sealed and stored at −20°C until use. 
Compounds were combined and diluted in PBS to obtain five 
concentrations ranging between 0.025 nM and 0.25 mM. 20 µl of 
each concentration were added to 30 µl of cell media containing 
5 × 103 neutrophils to obtain compound concentrations ranging 
between 0.01 nM and 100 µM.
rOs Quantification
Neutrophils were diluted in glucose-supplemented PBS and 
seeded at 1 × 105 cells/well in white 96-well plates (Costar 3912), 
pre-treated overnight with 1% bovine serum albumin (BSA; 
Sigma A4503) in PBS. ROS release was quantified by using an 
enhanced chemiluminescence assay as previously described in 
Matthews et al. (35). Neutrophils were incubated with 450 nM 
Luminol (Sigma A8511) in a luminometer (Berthold Tristar2 
LB942) for 30 min before stimulation and further incubation for 
up to 3 h. Readings were obtained at 37°C as relative light units.
Fluorometric Quantification of neT-Dna
Neutrophils were diluted in RPMI (Sigma R7509) and seeded 
at 1 × 105 cells/well, unless otherwise specified, in clear 96-well 
plates (Costar 3370), pre-treated overnight with PBS 1% BSA. 
Fluorometric quantification of NET-DNA was performed 
according to the protocol previously described by Palmer et al. 
(5). Neutrophils were pre-incubated at 37°C in 5% CO2 for 30 min 
prior to stimulation and further incubation at 37°C in 5% CO2 for 
up to 4 h. Post-incubation samples were treated for 10 min with 
1  unit/ml micrococcal nuclease (MNase; Worthington 4789), 
centrifuged for 10 min at 1,800 rcf and 150 µl of supernatant was 
transferred to a black 96-well plate (Costar 3915). NET-DNA was 
stained with 1 µM Sytox green® (Invitrogen S7020) and quanti-
fied with a fluorometer (Berthold Twinkle2 LB970; ex:485  nm/
em:525 nm). Readings were obtained at 37°C as arbitrary fluo-
rescence units.
hca of neTs
Neutrophils were diluted in RPMI and seeded at 1 × 105 cells/well, 
unless otherwise specified, in black, clear-bottom 96-well plates 
(Greiner Bio-one 655096), and pre-treated overnight with PBS 
1% BSA. Neutrophils were pre-incubated at 37°C in 5% CO2 for 
30 min prior to stimulation and further incubated at 37°C in 5% 
CO2 for up to 4 h. Post-incubation, neutrophils were fixed with 
4% PFA and stained with 1 µM Sytox green® or 20 µg/ml Hoechst 
33342 (Sigma 14533).
hcs of neTosis Modulators
Neutrophils were diluted in RPMI and 5 × 103 cells were seeded in 
black, clear-bottom 96-well plates (Greiner Bio-one 781096). The 
56-compound library, at the range of concentrations specified in 
Table S1 in Supplementary Material, was applied to the seeded 
neutrophils followed by 30 min incubation at 37°C in 5% CO2. 
Subsequently, where specified, NETs were induced with PMA as 
described above and following 3  h incubation, cells were fixed 
with 4% Formaldehyde and stained with 20 µg/ml Hoechst 33342.
image acquisition for hca and hcs
Samples were loaded onto the Cellomics™ ArrayScan™ (Thermo- 
Fisher Scientific VTI) and high-resolution images of 30 fields/
well were acquired and captured using an automated excitation 
filter wheel and automated Observer Z1 inverted microscope. 
Operations were driven by the HCS Studio 2.0 Client Software 
(ThermoFisher Scientific VTI) using a range of feature settings for 
autofocus, auto exposure, and cell sub-population.
automated image analysis
Automated image analysis was performed using the ArrayScan 
HCS Reader software (Cellomics ThermoFisher) employing 
algorithms for Compartmental, Tube formation, NET detection 
or Nuclear decondensation analysis. Parameters for cell identifi-
cation and exclusions were optimized for NETs or nuclei analysis 
(Imagen Therapeutics Ltd., UK).
statistics
Statistical analysis was performed using Prism versions 6 and 7 
(GraphPad). Each experiment was performed in triplicate and on 
at least three occasions using cells from different healthy volunteers. 
Statistical tests were two-sided, with significance defined at α = 0.05.
resUlTs
identification of an neT Fixation Protocol 
suitable for Use with hca
Investigating biological samples using HCA requires cell ima-
ging for accurate and rapid examination which, in turn, requires 
fixation and appropriate staining to preserve cellular features 
(26). Previously reported neutrophil fixation protocols involve 
numerous wash steps prior to image acquisition and analysis (36). 
Notably, the mechanical action applied during these wash steps 
can result in the loss of sample material and, in particular, the 
disruption of NET structures. Subsequently, we have established 
an appropriate protocol for NET fixation using PFA in microplate 
formats in order to prevent material loss and artifact generation. 
Images of NETs before and after modifications of the fixation 
protocol were observed to identify their effect on sample integrity. 
Assay variations included applying in different orders of the fixa-
tion protocol the addition of PFA, wash steps, and centrifugation 
procedures. Following a qualitative assessment of the outcomes 
of the various fixation protocols (data not shown), we identified 
the most appropriate protocol as consisting of careful addition of 
PFA directly into stimulated NET cultures followed by centrifu-
gation and washing with PBS as described in Section “Materials 
and Methods.” Representative images of the outcome pre- and 
post-fixation are provided in Figure 1. Notably the fixation agent 
directly interacts with the stimulated NETs potentially protect-
ing them from further downstream mechanical disruption that 
may result from subsequent steps in the procedure. Differences 
between pre- and post-fixation are not easily identifiable indicat-
ing the fixation protocol successfully preserves sample integrity.
FigUre 1 | Images of neutrophil extracellular traps (NETs) before (a) and after (B) fixation with PFA. Images representative of independent experiments acquired 
before (a) and after (B) the fixation procedures. NETs were visualized at 10× magnification with fluorescence microscopy (Nikon Eclipse TE300) upon Sytox green 
staining. Scale bars are shown.
4
Chicca et al. HCA Screening of NET Modulators
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 337
Optimization and Validation of hca 
Parameters for neT analysis
High-content analysis parameters were explored and optimized 
in order to develop an innovative high-throughput automated 
approach for NET analysis that utilized quantitative imaging for 
monitoring neutrophils, their nuclei and NET-related responses. 
Image analysis was performed using a bioinformatics software with 
built-in algorithms suitable for a diverse range of biological applica-
tions. Initially, two pre-existing algorithms, namely “Compartmental 
Analysis” and “Tube Formation,” were assessed for neutrophil and 
NET identification and analysis. NETs were induced by PMA 
stimulation and fixed with PFA. Neutrophil nuclei and NET struc-
tures were stained with Sytox green®. Images were acquired using 
the ArrayScan™ and analyzed using the HCS Reader software. 
NETs could potentially be recognized using the Compartmental 
Analysis algorithm, which quantifies the DNA in the circular space 
surrounding the nucleus (Figure 2A), or by the Tube Formation 
algorithm which quantifies DNA filaments extruded into the 
extracellular space (Figure 2B). Although NET quantification was 
effectively performed, we identified several limitations with these 
approaches including the lack of detection of early time-points of 
NET formation (data not shown). Therefore, two bespoke algo-
rithms were developed for NET analysis and were termed “Nuclear 
Decondensation” and “NET Detection.” These algorithms were 
developed for the simultaneous monitoring of two fundamental 
characteristics of NET release, respectively, including nuclear decon-
densation (Figure 2C) and the subsequent release of DNA into the 
extracellular space (Figure 2D).
The NET Detection algorithm was designed to identify 
filaments of extracellular DNA and to provide information on 
area, size, and intensity of those selected sections. Subsequently, 
we applied the NET Detection algorithm for the quantification 
of PMA-induced NET release over a 3-h time-course. Results 
indicated the technique detected NET units as early as 60 min 
after exposure to the stimulus, this detection then increased and 
peaked at 3 h. Interestingly, a relatively low amount of NETs were 
also identified immediately after PMA treatment. These data 
suggest HCA might be able to identify very early stages of NET 
formation as nuclear changes have been observed as rapidly as a 
few seconds after stimulation [data not shown and in Ref. (3, 4, 
24)]. The algorithm also identified relatively low amounts of NETs 
in unstimulated neutrophils and this marginally increased by 90 min 
(Figure 3A). The accuracy of the HCA approach and data were 
further validated by comparison with a standard quantification 
method. NET analysis was performed by HCA and compared 
with standard fluorometric quantification, which determined 
levels of extracellular NET-DNA post-MNase digestion. Data 
obtained using the fluorometric quantification identified a simi-
lar trend in PMA-stimulated NET production and confirmed the 
validity of HCA data (Figure 3B).
The sensitivity of the NET Detection algorithm was further 
evaluated using a range of neutrophil densities of between 1,000 
and 100,000 cells/well which were subsequently stimulated or 
unstimulated with PMA for 3 h. The NET Detection algorithm 
outputs were compared, again, with data obtained by the standard 
fluorometric assay for validation purposes. The NET Detection 
algorithm registered significantly higher levels of NETs in PMA-
stimulated compared with unstimulated neutrophils seeded at 
50,000 cells/well and higher (Figure 4A). A similar trend of NET 
production was confirmed following fluorometric quantification, 
which also showed significant increases in PMA-induced NETs 
compared with controls in neutrophils seeded at 50,000 cells/well 
and above. This increase was also detected with as few as 5,000 
neutrophils/well (Figure  4B). These validated results indicate 
that the HCA algorithm allowed sensitive and accurate NET 
quantification in samples with seeding densities above 50,000 
neutrophils/well in a microplate format.
Alongside the algorithm for NET structure analysis, a further 
algorithm was developed to acquire information on cells in the 
early stages of NET formation, based on monitoring changes in 
nuclear morphology and chromatin decondensation. Monitoring 
nuclear area and staining intensity provides information on the 
state of chromatin decondensation and, therefore, can reportedly 
be used as a quantifiable indicator of the early stages of NET 
formation (24). The Nuclear Decondensation algorithm provided 
information on Hoechst-stained neutrophil nuclei and identified 
as “NET forming” those cells with relatively large areas and low 
signal intensity compared with unstimulated controls. Neutrophils 
FigUre 2 | High-content analysis algorithm recognition of neutrophils and 
neutrophil extracellular traps (NETs). Images of PMA stimulated neutrophils 
following DNA fluorescence staining. Nuclei are shown in a decondensed 
state following stimulation and Hoechst staining while extracellular DNA is 
visible following Sytox green staining. (i) Images acquired using the 
ArrayScan, and (ii) applied automatic algorithm recognition. (a) Application  
of the Compartmental Analysis algorithm for the identification of neutrophil 
nuclei (purple) and NETs (blue). (B) Application of the Tube Formation 
algorithm for the identification of neutrophil nuclei (blue circles) and NETs 
(green, orange, yellow, and purple). (c) Application of the Nuclear 
Decondensation algorithm for the identification of neutrophil nuclei (circled  
in red). (D) Application of the NET Detection algorithm for the identification  
of NETs (green areas) while excluding intact cells (circled in orange).  
Scale bars represent 200 µm.
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were stimulated with PMA or were unstimulated (controls) for 
3 h (Figures 5A,B). Results shown in Figure 5D indicated the 
Nuclear Decondensation algorithm in unstimulated neutrophil 
nuclei calculated an average nuclear area of between 500 and 700 
pixels throughout the 4-h incubation period. A similar nuclear area 
was calculated in PMA-stimulated neutrophils for up to 3 h and 
increased to above 1,000 pixels being detected after 4 h. Opposing 
trends were seen for the analysis of nuclear staining intensity. 
PMA-stimulated neutrophil nuclear intensity was constantly 
found to be 200 units below the measured intensity in unstimulated 
neutrophils during the initial 3 h of exposure to PMA and decreased 
to 500 units at 4 h (Figure 5E). Nuclei which presented simulta-
neously enlarged areas and a diminished nuclear intensity were 
subsequently considered by the algorithm as NETotic events. Data 
presented in Figure 5F indicate the percentage of NET forming 
events calculated in unstimulated and stimulated neutrophils 
related to the previously described area and intensity data. The 
percentage of NET forming events remained at approximately 0% 
in unstimulated neutrophils, while in PMA-stimulated neutrophils 
approximately 60% of cells were determined to be in a NETosing 
state at 4 h exposure to PMA. To further validate and confirm the 
data obtained with the Nuclear Decondensation algorithm, we 
analyzed the set of images using the NET Detection algorithm. 
Interestingly, the trend for NET forming cells calculated with the 
Nuclear Decondensation algorithm was similar to the trend of NET 
release calculated using the NET Detection algorithm (Figure 5C): 
after 4 h exposure to PMA stimulated neutrophils presented higher 
levels of NET release compared with unstimulated neutrophils. 
Taken together, these data indicate that monitoring nuclear decon-
densation provides a valid indicator of NET forming activity and 
directly relates to NET formation.
high-Throughput screening of  
neTosis Modulators
The HCA method described above was applied for HCS of a phar-
maceutically derived compound library to identify modulators of 
NETosis. Celastrol-treated cells were used as inhibitory controls 
while Benzethonium Chloride was used to induce cytotoxicity 
and to discern NETosis from other forms of neutrophil cell death. 
After 30 min of compound pre-treatment, neutrophils were stim-
ulated with PMA or left unstimulated for 3 h. Following fixation, 
Hoechst was applied for nuclear staining and images were acquired 
using the ArrayScan™. HCA was performed using the Nuclear 
Detection algorithm and image analysis performed using two 
distinct methods for unstimulated and PMA-stimulated images. 
To identify whether compounds were able to induce NETosis 
in unstimulated conditions, rejection and threshold criteria for 
nuclear size and nuclear staining intensity were defined based on 
images of unstimulated and untreated neutrophils. The algorithm 
subsequently identified cells with increased nuclear size and with 
decreased nuclear intensity. Concomitantly increased size and 
decreased staining intensity was calculated by the algorithm and 
used as an indication of NETosis. Conversely, in order to identify 
whether compounds inhibited PMA-induced stimulation, rejec-
tion and threshold criteria were established based on images of 
PMA stimulated neutrophils with untreated neutrophils used as 
controls. In this case, the algorithm determined the proportion of 
cells with increased or decreased levels of both nuclear size and 
staining intensity compared with control cells. HCS identified 
17 compounds potentially inducing NETosis in unstimulated 
neutrophils, while 13 compounds were potentially identified 
as inhibiting NETosis and 13 compounds potentially enhanced 
PMA-induced NETosis (Figure S1 in Supplementary Material). 
Rapamycin and Lapatinib treatments resulted in inhibition of 
NETosis at relatively low doses and increased NETosis at higher 
doses, while Bosutinib treatment resulted in an opposing effect. 
FigUre 4 | Neutrophil extracellular traps (NET) quantification in a range of cell densities: high-content analysis (HCA) vs fluorometric assay. Neutrophils seeded at a 
range of concentrations in a 96-well plate and stimulated for 3 h with PMA (gray bars) or unstimulated (black bars). NET quantification by HCA (a) and fluorometric 
assay (B). Values are expressed as units of fluorescent signal or arbitrary fluorescence units (AFU) and as mean ± SEM. Statistical significance calculated using 
Sidak’s multiple comparison test (n = 3; **p < 0.01, ****p < 0.0001).
FigUre 3 | Time-course for neutrophil extracellular trap (NET) quantification: high-content analysis (HCA) vs fluorometric assay. Time-course of NET release in 
unstimulated and PMA-stimulated neutrophils up to 3 h. Comparison between HCA (a) and fluorometric (B) quantification. Values are expressed as units of 
fluorescent signal or arbitrary fluorescence units (AFU). Data represent duplicate means ± SEM.
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The compounds exhibiting modulatory activity in unstimulated 
and PMA-stimulated neutrophils were selected for further 
screening.
Images associated with the compounds identified by the initial 
HCS were further analyzed using the HCS Reader Software. The 
nuclei in each image were analyzed for false-negative or false-
positive events and for apoptosis-related phenotypes as previously 
identified in neutrophils by Fuchs et al. (4). Although apoptotic 
bodies were visible as black spots, the nuclei still presented similar 
features to NETosing activity, which was misinterpreted by the 
algorithm and, therefore, these were manually excluded from the 
selection process (data not shown).
Following extensive literature searching, those compounds 
that were associated with neutropenia or other forms of neutrophil 
cell death were also excluded from further study. Subsequently, 
of the 56 compounds initially screened for modulation of NET 
formation, 8 were selected for further downstream characteriza-
tion (listed in Table  1) as NET-inducers, inhibitors or with a 
biphasic modulatory activity. Images in Figure  6 show PMA 
stimulated and compound-treated neutrophils. PMA stimulated 
nuclei (Figure 6A), utilized for the determination of nuclear size 
and intensity thresholds, presented a characteristic NETosing 
morphology. In Figure 6B, Celastrol-treated neutrophils, as expec- 
ted, exhibited nuclei with characteristically unstimulated features 
and represented controls for inhibitory activity (33).
neutrophil Dose–responses to  
selected compounds
The eight selected compounds were characterized for their 
neutrophil modulatory activity using more targeted approaches. 
Compounds were simultaneously tested in neutrophils from three 
donors at a range of concentrations from 1 nM to 10 µM. PMA 
treatment was used as a positive control for stimulation, while 
Celastrol and media alone were used as a negative control and to 
provide baseline readouts, respectively. Intracellular and extracel-
lular ROS productions were monitored by chemiluminescence 
assay. Simultaneously, their ability to induce NETosis was evalu- 
ated by fluorometric quantification.
FigUre 5 | Time-course analysis of neutrophil extracellular trap (NET) formation as determined using the Nuclear Decondensation algorithm. Representative 
high-resolution images of (i) Hoechst-stained nuclei and (ii) Sytox-stained NETs in (a) unstimulated and (B) PMA stimulated neutrophils at 240 min. Time-point NET 
quantification using high-content analysis in unstimulated (continuous line) vs PMA-stimulated (dashed line) neutrophils for up to 240 min (scale bars represent 
200 μm). (c) Quantification of NET structures with the NET Detection algorithm compared with (D) nuclear area analysis, (e) nuclear intensity analysis, and  
(F) percentage of NET forming events calculated by the Nuclear Decondensation algorithm (n = 3).
TaBle 1 | Summary of the eight selected neutrophil extracellular trap (NET) modulating compounds, their known molecular targets and induced nuclear phenotype.
compound Target of inhibition induced nuclear phenotype Type of modulator
Crizotinib Anaplastic lymphoma kinase/Proto-oncogene 1 
receptor (ROS1) tyrosine kinase (TK) (37)
Decondensed state and visible extracellular DNA 
(Figure 6c)
NETosis inducer
Lapatinib Human epidermal growth factor receptor/epithelial 
growth factor receptor (EGFR) TK (38)
Decondensed state at high dosage (Figure 6D) and 
condensed state at low dosage (data not shown)
Biphasic (inhibition at low dosage and 
induction at high dosage)
Carmustine Glutathione reductase (39) Condensed state (Figure 6e) NETosis inhibitor
Erlotinib Epithelial growth factor receptor (EGFR) TK (40) Condensed state (Figure 6F) NETosis inhibitor
Bosutinib Src family kinases (41) Condensed state at high dosage (Figure 6g) and 
decondensed state at low dosage (data not shown)
Biphasic (induction at low dosage and 
inhibition at high dosage)
Ponatinib Vascular endothelial growth factor receptor/fibroblast 
growth factor receptor TK (42)
Decondensed state and visible extracellular DNA 
(Figure 6h)
NETosis inducer
Rapamycin Mammalian target of rapamycin/hypoxia-inducible 
factor 1α (32)
Decondensed state at high dosage (Figure 6i) and 
condensed state at low dosage (data not shown)
Biphasic (inhibition at low dosage and 
induction at high dosage)
Nilotinib Platelet-derived growth factor receptor TK (43) Condensed state (Figure 6J) NETosis inhibitor
7
Chicca et al. HCA Screening of NET Modulators
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 337
Neutrophil ROS production was evaluated for 3 h following 
compound treatment. PMA stimulation effectively induced ROS 
production, while data indicated none of the eight compound 
treatments induced the activation of the ROS cascade (Figure S2 
in Supplementary Material). Celastrol treatment resulted in 
statistically significant lower levels of ROS compared with media 
control, indicating the compound-driven inhibition may also sup-
press the normal metabolic activity of unstimulated cells. Similar 
statistically significant differences were detected with Bosutinib 
and Ponatib treatments at relatively high doses (respectively, at 
10 µM and at 1 and 10 µM), indicating the two compounds exert 
inhibitory effects similar to that of Celastrol.
Dose–response induction of NET formation in unstimulated 
neutrophils was evaluated by fluorometric measurement of extra-
cellular NET-DNA release following 3 h treatment with the selected 
compounds. Among the eight compounds tested, only Crizotinib 
treatment at 10 µM induced a significantly higher amount of NET-
DNA release compared with the unstimulated/untreated control 
FigUre 6 | Images of compound-treated neutrophil nuclei. Representative images of 3 h PMA-stimulated neutrophil nuclei (a) untreated or (B) pre-treated with 
celastrol and the eight compounds selected [(c) Crizotinib; (D) Lapatinib; (e) Carmustine; (F) Erlotinib; (g) Bosutinib; (h) Ponatinib; (i) Rapamycin; (J) Nilotinib] 
using high-content screening and manual screening applied at their highest concentration (10 µM). Nuclei and neutrophil extracellular traps are visible following 
Hoechst staining. Images are representative of three independent experiments. Scale bars represent 400 µm.
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(Figure 7A). Furthermore, Bosutinib and Ponatinib treatments 
at 10 µM resulted in increased NET-DNA release, although the 
difference compared with the media control was not statistically 
significant (Figure 7B). The remaining five compounds exhibited 
similar NET-DNA levels to that of the untreated control indicating 
their application to neutrophils did not trigger NET formation. 
Notably, the data for Crizotinib and Ponatinib treatments were 
consistent with the NET-inducing activity as identified by HCS.
compound Dose–response Modulation  
of PMa-induced neutrophil activation
The eight selected compounds were characterized for their ability 
to modulate responses in PMA activated neutrophils from three 
donors. Neutrophils were treated with the selected compounds at 
a range of concentrations from 1 nM to 10 µM and incubated for 
30 min prior to PMA stimulation for up to 3 h. Treatment with 
PMA only was utilized as the positive control, while Celastrol 
treatment was used as a control for inhibitory activity.
The dose–response modulation of PMA-induced ROS release 
was monitored for 3 h and the maximum levels of ROS produc-
tion following treatment were compared with the maximum 
levels registered in untreated cells throughout the stimulation 
period. Data presented in Figure  8 were normalized using the 
media-only control values in order to minimize the physiological 
differences between donors. Consistently, Celastrol treatment sig-
nificantly reduced PMA-induced ROS activity. Results presented 
in Figures  8A,B show an overall dose–response inhibition of 
ROS production following compound treatment compared with 
PMA-stimulated neutrophils, although, in general, these results 
were not statistically significant. Interestingly, Crizotinib treat-
ment at the highest dose (10 µM) was able to significantly reduce 
the amount of ROS produced in response to PMA stimulation 
(Figure  8A). Notably, Carmustine, Bosutinib, and Ponatinib 
treatments, all at the highest dose (10 µM), also reduced levels 
of PMA-induced ROS (Carmustine in Figure 8A, Bosutinib and 
Ponatinib in Figure  8B). These differences were, however, not 
statistically significant.
The dose–response modulation of PMA-induced NETosis by 
different compounds was evaluated by fluorometric measurement 
of extracellular NET-DNA release following 3 h incubation. Data 
presented in Figure 9 were normalized by media control values 
in order to minimize physiological differences between donors. 
Inhibition of NET release was identified following treatment with 
Lapatinib at 10 nM and 1 µM; Carmustine at 1 nM, 10 nM, and 
10 µM; and Erlotinib at 10 nM and 1 µM (Figure 9A). Interestingly, 
Crizotininb treatment at the highest dose (10 µM) resulted in more 
than threefold higher DNA release, although this was not statisti-
cally significant, compared with the untreated control (Figure 9A). 
Notably, these NET-modulation findings were consistent with their 
activity as identified by HCS. Statistical significance was identi-
fied for the inhibitory effects presented in Figure  9A. Notably, 
Ponatinib appeared to increase the PMA-induced NET production 
at higher doses (10 µM), while Rapamycin inhibited NET release 
at the lowest dose (1 nM) applied (Figure 9B). These differences 
were, however, not statistically significant.
DiscUssiOn
Several automated and high-throughput techniques have previ-
ously been proposed for NET analysis (21, 23, 24, 44), however, 
many of those approaches exhibit a number of shortcomings 
including lack of/limited reproducibility and the limitation of 
single parameter analysis. For the current studies, a protocol 
was developed and optimized for the analysis of NET formation 
using HCA. The main advantage of this approach is the potential 
to analyze a large population of neutrophils contained in the 
experimental sample, rather than limiting analyses to a selected 
proportion of the sample population.
FigUre 7 | Neutrophil extracellular trap (NET) production quantified in compound-treated neutrophils. Fluorometric NET quantification at 3 h in unstimulated 
neutrophils untreated or pre-treated with 10 µM Celastrol or the eight selected compounds using concentrations ranging from 1 nM to 10 µM [(a) Crizotinib, 
Lapatinib, Carmustine, Erlotinib; (B) Bosutinib, Ponatinib, Rapamycine, Nilotinib], or stimulated with 50 nM PMA. Values are expressed as mean arbitrary fluorescence 
units (AFU) ± SEM. Statistical significance was calculated using the Kruskal–Wallis’s multiple comparison test (n = 3; *p < 0.05 compared with PBS control values).
FigUre 8 | Compound inhibition of PMA-induced ROS. ROS quantification in neutrophils stimulated for 3 h with 50 nM PMA and untreated or pre-treated with 
10 µM Celastrol and the eight selected compounds at concentrations of between 1 nM and 10 µM [(a) Crizotinib, Lapatinib, Carmustine, Erlotinib; (B) Bosutinib, 
Ponatinib, Rapamycine, Nilotinib]. Values are normalized to the media control and expressed as mean relative light units (RLU) ± SEM. Statistical significance was 
calculated using the Kruskal–Wallis’s multiple comparison test (n = 3; *p < 0.05 compared with PMA control values).
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A suitable protocol for the preservation of NET samples 
was developed to enable the use of HCA. Particular attention 
was paid to optimizing the fixative procedures required for 
sample preservation, since NETs are fragile structures requir-
ing maintenance of their integrity for accurate analysis (7). The 
majority of fixation protocols tested were relatively aggressive 
and caused loss of NET filaments and alterations in the spatial 
organization of NETs. This property may have contributed to 
issues identified in previously published NET studies, which 
largely employed sample preparation on glass slides and used 
microscopic observation for analysis (45). Subsequently, there 
is a need for standardization of objective analytical protocols, 
which are automated and reproducible for NET analysis (21). 
Once suitable conditions for NET analysis were identified and the 
fixation protocol was optimized for NET preservation, HCA was 
performed to quantify the associated features of NET formation 
and release. The software employed for HCA automated image 
analysis is designed with a number of built-in algorithms suitable 
for a wide range of biological applications. The settings of two of 
these algorithms had characteristics that were deemed appropri-
ate for the features of NET formation. These were assessed for 
their ability to identify neutrophil nuclei and the quantification 
of NET-related features. However, results obtained using these 
algorithms indicated that their application for NETosis exhibited 
key limitations, mostly due to the inaccurate identification of 
the characteristic web-like morphology of NETs. Two additional 
FigUre 9 | Compound inhibition of PMA-induced neutrophil extracellular traps (NETs). NET quantification in neutrophils stimulated for 3 h with 50 nM PMA and 
untreated or pre-treated with 10 µM Celastrol and the eight selected compounds at concentrations of between 1 nM and 10 µM [(a) Crizotinib, Lapatinib, 
Carmustine, Erlotinib; (B) Bosutinib, Ponatinib, Rapamycine, Nilotinib]. Values were normalized to the media control and expressed as mean arbitrary fluorescence 
units (AFU) ± SEM. Statistical significance was calculated using the Kruskal–Wallis’s multiple comparison test (n = 3; ns = non-significant, *p < 0.05, **p < 0.01 
compared with PMA control values).
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algorithms were, therefore, specifically developed for the analysis 
of NETosis-related features.
The HCA method and the Nuclear Decondensation algorithm 
optimized for NET analysis were applied for the screening of a 
compound library, with the aim of identifying modulators which 
could increase or reduce NET formation and which, therefore, 
may have potential in therapeutic applications. The library 
employed was originally developed for cancer cell treatments and 
comprised a wide range of pharmaceutically relevant compounds 
with varied targets for immune cell modulation. Following the 
initial HCS, further manual screening approaches confirmed 
the identification of eight modulators of NETosis among the 
original 56 compounds tested. These eight compounds were sub- 
categorized based on their effects on NET formation as being 
inducers, inhibitors, or biphasic modulators. Notably, the eight 
compounds have been found to modulate multiple intracellular 
pathways in cancer cells and those relevant to neutrophil or 
NETosis activity are summarized in Table 1. Several of these 
compounds have been previously associated with NET forming 
pathways. Indeed, Carmustine’s inhibitory activity has been shown 
to target glutathione reductase (39). This enzyme catalyzes the 
reduction of glutathione (GSH) from its oxidized state (GSSG) and 
is responsible for maintaining a balanced redox state in neutrophils 
(46). Interestingly, elevated levels of GSSG have been related to the 
hyperactivity of neutrophils from periodontitis patients (47) and 
Yan et al. (48) demonstrated that glutathione reductase activity, 
despite having an antioxidant function, is essential for the pro-
duction of murine NETs. Recently, a further study demonstrated 
that glutathionylation is involved in the production of NETs using 
murine models (49). Furthermore, Bosutinib is an inhibitor of the 
Src family kinases which have been previously identified as play-
ing a role in regulating yeast-induced NET production (50, 51) 
Rapamycin has also been previously shown to regulate NETosis 
through the mTOR pathway and the induction of the hypoxia-
inducible factor-1α (HIF-1α) (32, 52, 53).
Other potentially novel signal transduction pathways regulating 
NETosis were highlighted by the effects of the other compounds 
and identified roles for several receptor-associated tyrosine 
kinases. Interestingly, data presented here indicate that the MAPK 
pathway strongly associates with NET formation. These data are 
consistent with the findings of previous studies (44, 54, 55) and 
could represent an interesting target for the treatment of NET-
related diseases, since MAPK-driven phosphorylation controls 
a wide-range of pro-inflammatory signaling responses. Further 
investigation is, therefore, required to understand the molecular 
association between NETosis and the pathways identified by HCS 
and these have the potential to be explored in more detail using the 
HCA platform. As the identification of NETosis regulators might 
have a significant impact for the treatment of high-risk patients, 
future research should focus on NET-related pathways and iden-
tifying targets for therapeutic applications. Indeed, future work 
could employ HCA for the screening of a larger and more targeted 
compound library, potentially focusing on the MAPK pathway 
as well as ones containing neutrophil receptor ligands. Such data 
would provide a better understanding of the regulation of NET 
formation and identify further compounds with therapeutic utility.
The effects of the eight compounds selected by HCS were 
further explored using specific low-throughput analysis of ROS 
and NET production (summarized in Table S2 in Supplementary 
Material). Compound treatment was assayed in unstimulated 
and stimulated neutrophils. Notably, data obtained using three 
different donors were variable and this likely affected the statis-
tical significance of the findings presented here. Indeed donor 
variability identified by low-throughput analysis of NETs here 
and by previous publications (21, 56) may be overcome in future 
studies by the application of the HCA method in which levels 
of activation are standardized by baseline and maximum activa-
tion status using the algorithmic image analysis. Furthermore, 
using HCA, a greater number of individual donor samples can be 
simultaneously analyzed adding to the study power.
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It can be postulated that a delicate equilibrium exists between 
NET formation and removal in order to ensure both the adequate 
protection against infection and, at the same time, avoiding 
exposing the host tissues to injurious NET content for a prolonged 
time period. Indeed, when this equilibrium is lost, an unbalanced 
immune response results in inflammation and disease progression 
(14). Anti-inflammatory drugs have previously been tested on 
neutrophils in order to inhibit NET formation (30, 31), however, 
interestingly, in this study, modulators with both effects, of induc-
ing and inhibiting NETosis, were identified. The identification of 
compounds that exhibit a broad range of modulatory activity 
on NET formation offers the potential to establish a homeo-
static balance in patients affected by NET-associated diseases. 
Notably, Crizotinib, Bosutinib, and Ponatinib, were identified as 
NET inducers and may, therefore, have application for treating 
NET-deficiency in patients such as those with CGD (4); indeed 
and importantly, data indicate that their intracellular targets 
modulate NET formation downstream of the NADPH-Oxidase 
components. Furthermore, Bosutinib and Ponatinib together 
with Celastrol, efficiently decreased baseline and PMA-induced 
ROS production, suggesting treatment with these compounds 
may have therapeutic application for the hyper-responsiveness 
of neutrophils from patients affected by periodontitis (35, 57). 
Compounds identified as NET inhibitors, including Lapatinib, 
Carmustine, and Erlotinib, may be employed for the treatment of 
conditions in which excess or aberrant NET production is related 
to disease development such as CF, SLE, and RA (8, 12, 58). The 
pathways described above, however, require further investiga-
tion to identify the specific molecular mechanism behind their 
modulation of NET production.
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